ADMA Biologics (NASDAQ:ADMA) Stock Rating Upgraded by StockNews.com

ADMA Biologics (NASDAQ:ADMA) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

A number of other brokerages also recently weighed in on ADMA. Cantor Fitzgerald increased their price objective on shares of ADMA Biologics from $5.00 to $6.00 and gave the company an “overweight” rating in a research report on Thursday, August 10th. HC Wainwright upped their target price on shares of ADMA Biologics from $4.50 to $5.00 and gave the company a “buy” rating in a report on Thursday, August 10th. Raymond James upped their target price on shares of ADMA Biologics from $5.00 to $6.00 and gave the company a “strong-buy” rating in a report on Thursday, August 10th. Finally, Mizuho upped their target price on shares of ADMA Biologics from $6.00 to $7.00 in a report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $6.00.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $3.77 on Friday. ADMA Biologics has a 1 year low of $2.94 and a 1 year high of $4.65. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.35 and a quick ratio of 2.49. The company’s 50-day moving average is $3.52 and its 200 day moving average is $3.75. The stock has a market capitalization of $847.91 million, a P/E ratio of -34.27 and a beta of 0.79.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The business had revenue of $67.30 million for the quarter, compared to analyst estimates of $62.13 million. ADMA Biologics had a negative net margin of 9.74% and a negative return on equity of 13.54%. ADMA Biologics’s quarterly revenue was up 63.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.08) earnings per share. On average, sell-side analysts expect that ADMA Biologics will post -0.06 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In other news, Director Young Kwon acquired 25,000 shares of ADMA Biologics stock in a transaction dated Thursday, August 24th. The stock was purchased at an average cost of $3.90 per share, with a total value of $97,500.00. Following the completion of the purchase, the director now directly owns 277,401 shares in the company, valued at approximately $1,081,863.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other ADMA Biologics news, Director Jerrold B. Grossman bought 130,000 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The shares were purchased at an average cost of $3.71 per share, for a total transaction of $482,300.00. Following the transaction, the director now owns 443,265 shares of the company’s stock, valued at $1,644,513.15. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Young Kwon purchased 25,000 shares of the stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average cost of $3.90 per share, with a total value of $97,500.00. Following the acquisition, the director now owns 277,401 shares in the company, valued at approximately $1,081,863.90. The disclosure for this purchase can be found here. Insiders sold a total of 2,405,351 shares of company stock valued at $9,875,175 over the last three months. Corporate insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in ADMA Biologics by 8.5% in the first quarter. BlackRock Inc. now owns 16,391,319 shares of the biotechnology company’s stock worth $54,255,000 after acquiring an additional 1,290,038 shares in the last quarter. State Street Corp boosted its position in shares of ADMA Biologics by 18.0% during the first quarter. State Street Corp now owns 12,988,589 shares of the biotechnology company’s stock valued at $42,992,000 after buying an additional 1,981,380 shares during the period. Vanguard Group Inc. boosted its position in shares of ADMA Biologics by 2.8% during the third quarter. Vanguard Group Inc. now owns 9,290,699 shares of the biotechnology company’s stock valued at $22,576,000 after buying an additional 250,455 shares during the period. Stonepine Capital Management LLC boosted its position in shares of ADMA Biologics by 14.8% during the second quarter. Stonepine Capital Management LLC now owns 8,793,321 shares of the biotechnology company’s stock valued at $32,447,000 after buying an additional 1,131,631 shares during the period. Finally, Millennium Management LLC boosted its position in shares of ADMA Biologics by 75.4% during the second quarter. Millennium Management LLC now owns 5,889,971 shares of the biotechnology company’s stock valued at $11,662,000 after buying an additional 2,531,272 shares during the period. Hedge funds and other institutional investors own 73.58% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.